drugset / Trial / NCT06701344

Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

NCT06701344

Phase 2 Not yet recruiting 7 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this observational study is to evaluate the safety and efficacy of Go-CHOP (Golidocitinib plus Cyclophosphamide, Hydroxydoxorubicin, Oncovin and Prednisone) in de novo intestinal T-cell lymphoma patients, The aim is to evaluate the complete response rate (CRR). Participants will receive Go-CHOP for 6 cycles every 21 days followed by either maintenance therapy or ASCT.

Timeline

Start
2024-12-04
Primary completion
2026-05-04
Completion
2027-12-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 750 mg/m2
Subject Doxorubicin Other / unclassified 50 mg/m2
Subject Golidocitinib Small molecule 150 mg
Subject Prednisone Other / unclassified 60 mg/m2
Subject Vincristine Small molecule 1.4 mg/m2